|
Your October 2014 digital issue of P&T journal is available.
This issue contains:
Feature articles
- The Clinical Trial Model Is Up for Review
Time, Expense, and Quality of Results Are at Issue, As Is the Relationship to Drug Pricing
Costly medications have raised questions about the role that long, complex clinical trials play in drug pricing. Approval of a drug takes, on average, 14 years, costs more than $2 billion, and has a high risk of failure. Participants are seeking alternatives.
- PHARMACOVIGILANCE FORUM
Pyrazinamide-Induced Hyperuricemia
Elevated uric acid levels can cause crystal deposition and may lead to gout, urolithiasis, and urate nephropathy. The authors report on the case of a 34-year-old male whose hyperuricemia was associated with the antituberculous drug pyrazinamide.
- Lung Cancer Research Is Taking On New Challenges
Knowledge of Tumors' Molecular Diversity Is Opening New Pathways to Treatment
Lung cancer treatment has undergone significant change in the past decade, leading to remarkable growth in the number and variety of therapeutic options. This shift reflects, in part, a significant refinement in the molecular categorization of lung cancer.
- Medical Applications for 3D Printing:
Current and Projected Uses
3D printing is expected to revolutionize health care through uses in tissue and organ fabrication; creation of customized prosthetics, implants, and anatomical models; and pharmaceutical research regarding drug dosage forms, delivery, and discovery.
- PIPELINE PLUS
Steady Progress on Parkinson's Disease
Treatment of Parkinson's disease is expected to lead to $3.56 billion in global sales in 2022. Manufacturers are reformulating medications in addition to creating new ones.
Plus our regular columns: Medication Errors, Prescription: Washington, New Drugs/Drug News/New Medical Devices, Pharmaceutical Approval Update, and Drug Forecast.
Click here to begin reading the current issue.
Click here to subscribe to P&T journal
Call for Papers
P&T is accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please contact Sonja Sherritze, via phone (267-685-2779) or mobile 267-907-5642) or e-mail (ssherritze@medimedia.com) for more information.
We hope you enjoy this issue of P&T. If you have any comments or questions about this digital format, please e-mail us at mail@ptcommunity.com. Sonja Sherritze Editor |
Posts
